Member ResourcesPipelines in Oncology
http://www.bms.com
Rob Kramer - Vice President of Discovery Biology
Steve Auerbach - Vice President of Research and Development
Presentations on: - Ixempra
- Sprycel
- Erbitux
- Ipilimumab
- Tanespimycin
- XL-184
- IGF-R Antagonist
- VEGF R-2 Adnectin
- Inhibitor (CT-322)
- ErbB/VEGF Inhibitor
- Anti-CD 137 antibody
- Epothilone-Folate
- SMO Inhibitor
- Cdc7 Inhibitor (XL-413)
- Anti-CS1 antibody (Elotuzumab)
- Adnectin Bispecific Inhibitor
- RAF Kinase Inhibitor (XL-281)
http://www.abraxisbio.com
Jose Iglesis, MD - Vice President for Global Clinical Development
David Brooks, MD, PhD - Medical Director for Global Clinical Development
Kathy Meyer - Medical Liaision
Presentations on: - Nab-paclitaxel
- ABI-008 (Nab-docetaxel)
- ABI-009 (Nab-rapamycin)
- ABI-010 (Nab-17AAG-Hsp90 inhibition)
- ABI-011 (Nab-dual mechanism inhibitor)
- ABI-0013 (Nab - novel taxane)
http://www.novartis.com
William Sellers, PhD - Vice President, Global Head Oncology
Barbara Weber, MD - Senior Vice President of Translational Medicine
Presentations on: - Therapeutic Targeting of Oncogenic Pathways
http://www.avilatx.com
Erica Evans, PhD - Senior Scientist
Mariana Nacht, PhD - Director, Molecular and Cell Biology
William Westlin, PhD - Vice President, Preclinical Research
Presentation on: - AVL291- btk inhibitor (B-cell malignancies)
- panErB inhibitor program
- PI3K inihbitor program
http://www.amgen.com
Sean Harper, MD - Senior Vice President Global Development and Chief Medical Officer
David Chang, MD, PhD - Vice President Global Development TA Head Hematology/Oncology
John Newcomb, PhD- Director Oncology Research
Douglas Saffran, PhD – Principal Scientist, Oncology Research
Presentation on: - Overview over Amgen pipeline, with focus on Angiopoietin-Tie2 Pathway (AMG 386), HER 3, HGS/SF- c-met pathway (AMG102).
http://www.osip.com
Marta Hamilton, PhD - Vice President, Preclinical Development and Pharmacology
Frank Richardson, PhD - Senior Director, Safety Assessment and Molecular Markers
Phil Rutledge, MA, MBA - Director, Medical Science Liaisons
Presentation on: - OSI Biomarkers and Diagnostics Efforts
http://www.astrazeneca.com
Louise Grochow, MD – Executive Director of Global Medical Science
Jeff Hanke, PhD – Vice President, Cancer Research
Greg Curt, MD – US Medical Science Lead, Oncology
Presentation on: - Overview of AstraZeneca Pipeline
http://www.ariad.com
Pierre F. Dodion, M.D. - Senior Vice President and Chief Medical Officer
Frank G. Haluska, M.D., Ph.D. - Vice President, Clinical Research
Tim Clackson, Ph.D. - Senior Vice President and Chief Scientific Officer
Presentation on: - Deforolimus: oral mTOR inhibitor, currently in phase 3 development in sarcoma, as well as numerous phase 1 and 2 studies
- AP24534: once-daily oral pan-Bcr-Abl inhibitor, currently in phase 1 development in heme malignancies including CML; also an inhibitor of FGFRs and other angiogenesis-related targets
- ALK inhibitor: new program recently announced; a selective, orally active agent currently in preclinical development.
http://www.sanofi-aventis.us/live/us/en/index.jsp
Nassir Habboubi - Vice President, Head US Medical
Svetlana Kobina, MD PHD - Associate Vice President USMA - GI and Lung
Grannum Sant, MD - Vice President US Medical -Urology
Mohamed Zaki, MD PhD - R&D US Clinical Research Unit
Presentation on: - Afibercept (VEGF-Trap, an anti-angiogenesis agent)
- Two Taxane Analogs: Larotaxel and XRP6258
- Alvocidib (Flavopiridol, a pan CDK-inhibitor)
- AVE8062 (Vascular Disruption Agent)
- Trovax (Therapeutic vaccine)
http://www.wyeth.com
Jay Gibbons – Associate Vice President Discovery
Charlie Zacharchuk - Senior Director CR&D/Early development
Anna Berkenblit - Director, Medical Monitor Neratinib program
Chris Coughlin - Director, Medical Monitor neratinib / translational medicine expert
Presentation on: - Wyeth Discovery Compounds/ Research Platform
- Neratinib - Irreversible panErbB inhibitor
- SKI 606 - Src Abl Kinase Inhibitor for Breast Cancer
|
|
|
|
